Camber Capital Management LP Global Blood Therapeutics, Inc. Transaction History

Camber Capital Management LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$37.65 - $63.77 $1.88 Million - $3.19 Million	-50,000 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$52.76 - $74.49 $2.64 Million - $3.72 Million	50,000 New	50,000 $2.76 Million
Q1 2020 May 15, 2020	SELL	$41.72 - $87.2 $30.5 Million - $63.7 Million	-730,000 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$45.7 - $81.86 $33.4 Million - $59.8 Million	730,000 New	730,000 $58 Million
Q2 2019 Aug 14, 2019	SELL	$52.6 - $63.29 $94.7 Million - $114 Million	-1,800,000 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$39.99 - $53.48 $18 Million - $24.1 Million	-450,000 Reduced 20.0%	1,800,000 $95.3 Million
Q4 2018 Feb 14, 2019	BUY	$31.54 - $46.67 $5.52 Million - $8.17 Million	175,000 Added 8.43%	2,250,000 $92.4 Million
Q3 2018 Nov 14, 2018	SELL	$38.0 - $51.1 $4.75 Million - $6.39 Million	-125,000 Reduced 5.68%	2,075,000 $78.9 Million
Q2 2018 Aug 14, 2018	BUY	$38.7 - $50.15 $38.7 Million - $50.2 Million	1,000,000 Added 83.33%	2,200,000 $99.4 Million
Q1 2018 May 15, 2018	BUY	$39.6 - $65.9 $15.8 Million - $26.4 Million	400,000 Added 50.0%	1,200,000 $58 Million
Q4 2017 Feb 14, 2018	BUY	$29.7 - $45.7 $23.8 Million - $36.6 Million	800,000	800,000 $31.5 Million

288K

Ticker GBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,476,200
Market Cap $4.62B
Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...

Get notified when there are updates to the investment portfolio of Camber Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Camber Capital Management LP with notifications on news.